Oral immunization with recombinant vaccinia virus prime and intramuscular protein boost provides protection against intrarectal simian-human immunodeficiency virus challenge in Macaques

Clinical and Vaccine Immunology

Volumn 23, Issue 3, 2016, Pages 204-212

  Thippeshappa, Rajesh ^a   Tian, Baoping ^a   Cleveland, Brad ^a   Guo, Wenjin ^a   Polacino, Patricia ^a   Hu, Shiu Lok ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; POL PROTEIN; POXVIRUS VECTOR; PROTEIN SF162; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 160; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; GP160 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INOCULATION; MACACA; MOUTH LESION; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUCOSAL IMMUNITY; RHESUS MONKEY; VACCINATION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; FUSION PROTEINS, GAG-POL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV-1; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MACACA MULATTA; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84962554198     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00597-15     Document Type: Article

References (50)

1. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459. http://dx.doi.org/10.1126/science.1531159.
2. Hu SL, Klaniecki J, Dykers T, Sridhar P, Travis BM. 1991. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res Hum Retroviruses 7:615-620. http://dx.doi.org/10.1089/aid.1991.7.615.
3. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82:638-651. http://dx.doi.org/10.1128/JVI.01691-07.
4. Polacino P, Cleveland B, Zhu Y, Kimata JT, Overbaugh J, Anderson D, Hu SL. 2007. Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. J Med Primatol 36:254-265. http://dx.doi.org/10.1111/j.1600-0684.2007.00243.x.
5. Polacino P, Stallard V, Montefiori DC, Brown CR, Richardson BA, Morton WR, Benveniste RE, Hu SL. 1999. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol 73:3134-3146.
6. Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, Richardson BA, Morton WR, Benveniste RE, Hu SL. 1999. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques. J Virol 73:8201-8215.
7. Polacino P, Stallard V, Klaniecki JE, Montefiori DC, Langlois AJ, Richardson BA, Overbaugh J, Morton WR, Benveniste RE, Hu SL. 1999. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 73:618-630.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
9. Veazey RS, Lackner AA. 2004. Getting to the guts of HIV pathogenesis. J Exp Med 200:697-700. http://dx.doi.org/10.1084/jem.20041464.
10. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. 2004. CD4-T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759. http://dx.doi.org/10.1084/jem.20040874.
11. Gallichan WS, Rosenthal KL. 1996. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 184:1879-1890. http://dx.doi.org/10.1084/jem.184.5.1879.
12. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S. 2011. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-280. http://dx.doi.org/10.1016/j.immuni.2011.01.015.
13. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med 11:S45-S53. http://dx.doi.org/10.1038/nm1213.
14. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 6:148-158. http://dx.doi.org/10.1038/nri1777.
15. Kanesaki T, Murphy BR, Collins PL, Ogra PL. 1991. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J Virol 65:657-663.
16. Meitin CA, Bender BS, Small PA, Jr. 1994. Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci U S A 91:11187-11191. http://dx.doi.org/10.1073/pnas.91.23.11187.
17. Moss B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93:11341-11348. http://dx.doi.org/10.1073/pnas.93.21.11341.
18. Moss B, Smith GL, Gerin JL, Purcell RH. 1984. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311:67-69 http://dx.doi.org/10.1038/311067a0.
19. Smith GL, Murphy BR, Moss B. 1983. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80:7155-7159. http://dx.doi.org/10.1073/pnas.80.23.7155.
20. Giavedoni L, Jones L, Mebus C, Yilma T. 1991. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no spock lesions. Proc Natl Acad Sci U S A 88:8011-8015. http://dx.doi.org/10.1073/pnas.88.18.8011.
21. Hochstein-Mintzel V, Stickl H, Huber HC. 1976. Oral immunization against smallpox. Dev Biol Stand 33:260-266.
22. Blancou J, Kieny MP, Lathe R, Lecocq JP, Pastoret PP, Soulebot JP, Desmettre P. 1986. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 322:373-375. http://dx.doi.org/10.1038/322373a0.
23. Rupprecht CE, Wiktor TJ, Johnston DH, Hamir AN, Dietzschold B, Wunner WH, Glickman LT, Koprowski H. 1986. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glyco-protein recombinant virus vaccine. Proc Natl Acad Sci U S A 83:7947-7950. http://dx.doi.org/10.1073/pnas.83.20.7947.
24. Brochier B, Boulanger D, Costy F, Pastoret PP. 1994. Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine 12:1368-1371. http://dx.doi.org/10.1016/0264-410X(94)90143-0.
25. Brochier B, Blancou J, Thomas I, Languet B, Artois M, Kieny MP, Lecocq JP, Costy F, Desmettre P, Chappuis G, Pastoret PP. 1989. Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: Innocuity to several non-target bait consuming species. J Wildl Dis 25:540-547. http://dx.doi.org/10.7589/0090-3558-25.4.540.
26. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. 1993. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 90:1882-1886. http://dx.doi.org/10.1073/pnas.90.5.1882.
27. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu SL, Smith GE, Fast PE, Koff WC, the NIAID AIDS Vaccine Clinical Trials Network. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with gp160 in vaccinianaive adults. J Infect Dis 167:533-537. http://dx.doi.org/10.1093/infdis/167.3.533.
28. Hu SL, Kosowski SG, Dalrymple JM. 1986. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320:537-540. http://dx.doi.org/10.1038/320537a0.
29. Joklik WK. 1962. The purification of four strains of poxvirus. Virology 18:9-18. http://dx.doi.org/10.1016/0042-6822(62)90172-1.
30. Guo W, Cleveland B, Davenport TM, Lee KK, Hu SL. 2013. Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expr Purif 90:34-39. http://dx.doi.org/10.1016/j.pep.2013.04.009.
31. Polacino P, Larsen K, Galmin L, Suschak J, Kraft Z, Stamatatos L, Anderson D, Barnett SW, Pal R, Bost K, Bandivdekar AH, Miller CJ, Hu SL. 2008. Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol 37(Suppl 2):S13-S23. http://dx.doi.org/10.1111/j.1600-0684.2008.00325.x.
32. Ho O, Larsen K, Polacino P, Li Y, Anderson D, Song R, Ruprecht RM, Hu SL. 2009. Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology 6:65. http://dx.doi.org/10.1186/1742-4690-6-65.
33. Hu SL, Zarling JM, Chinn J, Travis BM, Moran PA, Sias J, Kuller L, Morton WR, Heidecker G, Benveniste RE. 1989. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci U S A 86:7213-7217. http://dx.doi.org/10.1073/pnas.86.18.7213.
34. Fuller DH, Rajakumar P, Che JW, Narendran A, Nyaundi J, Michael H, Yager EJ, Stagnar C, Wahlberg B, Taber R, Haynes JR, Cook FC, Ertl P, Tite J, Amedee AM, Murphey-Corb M. 2012. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 7:e33715. http://dx.doi.org/10.1371/journal.pone.0033715.
35. Suryanarayana K, Wiltrout TA, Vasquez GM, Hirsch VM, Lifson JD. 1998. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses 14:183-189. http://dx.doi.org/10.1089/aid.1998.14.183.
36. Thomas I, Brochier B, Languet B, Blancou J, Peharpre D, Kieny MP, Desmettre P, Chappuis G, Pastoret PP. 1990. Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. J Gen Virol 71:37-42. http://dx.doi.org/10.1099/0022-1317-71-1-37.
37. Tuero I, Robert-Guroff M. 2014. Challenges in mucosal HIV vaccine development: Lessons from non-human primate models. Viruses 6:3129-3158. http://dx.doi.org/10.3390/v6083129.
38. Poles J, Alvarez Y, Hioe CE. 2014. Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. AIDS Res Hum Retroviruses 30:1027-1040. http://dx.doi.org/10.1089/aid.2014.0233.
39. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M. 2009. Correlation of vaccineelicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83:791-801. http://dx.doi.org/10.1128/JVI.01672-08.
40. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M. 2012. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 86:4644-4657. http://dx.doi.org/10.1128/JVI.06812-11.
41. Eugene HS, Pierce-Paul BR, Cragio JK, Ross TM. 2013. Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol J 10:102. http://dx.doi.org/10.1186/1743-422X-10-102.
42. Duerr A. 2010. Update on mucosal HIV vaccine vectors. Curr Opin HIV AIDS 5:397-403. http://dx.doi.org/10.1097/COH.0b013e32833d2e39.
43. Stahl-Hennig C, Kuate S, Franz M, Suh YS, Stoiber H, Sauermann U, Tenner-Racz K, Norley S, Park KS, Sung YC, Steinman R, Racz P, Uberla K. 2007. Atraumatic oral spray immunization with replicationdeficient viral vector vaccines. J Virol 81:13180-13190. http://dx.doi.org/10.1128/JVI.01400-07.
44. Bogers WM, Davis D, Baak I, Kan E, Hofman S, Sun Y, Mortier D, Lian Y, Oostermeijer H, Fagrouch Z, Dubbes R, Van Der Maas M, Mooij P, Koopman G, Verschoor E, Langedijk JP, Zhao J, Brocca-Cofano E, Robert-Guroff M, Srivastava I, Barnett S, Heeney JL. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382:217-225. http://dx.doi.org/10.1016/j.virol.2008.09.016.
45. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
46. Thomas MA, Tuero I, Demberg T, Vargas-Inchaustegui DA, Musich T, Xiao P, Venzon D, LaBranche C, Montefiori DC, DiPasquale J, Reed SG, DeVico A, Fouts T, Lewis GK, Gallo RC, Robert-Guroff M. 2014. HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology 471-473:81-92. http://dx.doi.org/10.1016/j.virol.2014.10.001.
47. Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L, Mulvania T, Anderson D, Greenberg PD, Hu SL, Haigwood NL. 2003. Multigene DNA priming-boosting vaccines protect macaques from acute CD4--T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 77:11563-11577. http://dx.doi.org/10.1128/JVI.77.21.11563-11577.2003.
48. Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B. 2002. Comparison of vaccine strategies using recombinant env-gag-pol MVAwith or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294:270-281. http://dx.doi.org/10.1006/viro.2001.1345.
49. Rasmussen RA, Hofmann-Lehman R, Montefiori DC, Li PL, Liska V, Vlasak J, Baba TW, Schmitz JE, Kuroda MJ, Robinson HL, McClure HM, Lu S, Hu SL, Rizvi TA, Ruprecht RM. 2002. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 31:40-60. http://dx.doi.org/10.1034/j.1600-0684.2002.1o019.x.
50. Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L. 2006. Immunization with HIV-1 SF162-derived envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349:276-289. http://dx.doi.org/10.1016/j.virol.2006.01.043.